Treatment of Male Breast Cancer Has Evolved From 2004 to 2014
MONDAY, Oct. 7, 2019 -- Treatment of male breast cancer (MBC) has evolved since 2004, with increases in various treatment modalities, according to a study published online Oct. 7 in Cancer.
Siddhartha Yadav, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues examined treatment patterns and prognostic factors for 10,873 MBC cases among men with TNM (tumor, node, metastases) stage I to stage III breast cancer diagnosed between 2004 and 2014 (median age, 64 years).
The researchers found that 24 percent of patients underwent breast-conserving surgery, while 70 percent of those undergoing breast conservation received radiotherapy. About 44 percent of patients received chemotherapy; of the patients with estrogen receptor-positive disease, 62 percent received endocrine therapy. In 35 percent of patients with lymph node-negative estrogen receptor-positive/human epidermal growth factor receptor 2-negative tumors, Oncotype DX was ordered. There was a significant increase in the rates of total mastectomy, contralateral prophylactic mastectomy, radiotherapy after breast conservation, ordering of Oncotype DX, and use of endocrine therapy during the study period. In a multivariate analysis, the investigators found that older age, black race, higher Charlson Comorbidity Index, high tumor grade and stage of disease, and undergoing total mastectomy were associated with worse overall survival. Better overall survival was seen in association with residing in a higher-income area, having progesterone receptor-positive tumors, and receipt of chemotherapy, radiotherapy, and endocrine therapy.
"The results of the current study highlight unique practice patterns and factors associated with prognosis in patients with MBC," the authors write.
Several authors disclosed financial ties to the biopharmaceutical industry.
© 2019 HealthDay. All rights reserved.
Posted: October 2019